Senores Pharmaceuticals Ltd has strengthened its product portfolio with the acquisition of 14 Abbreviated New Drug Applications (ANDAs) through its wholly-owned subsidiary. The company has entered into agreements to acquire these ANDAs from Dr. Reddy’s Laboratories and its affiliates.

The acquisition includes 13 USFDA-approved ANDAs and one pending approval, with a market potential of approximately $421 million (MAT December 2024, IQVIA) and $1.13 billion (MAT September 2024, Symphony) in the U.S. pharmaceutical market.

Senores Pharmaceuticals is funding this acquisition using proceeds from its Initial Public Offering (IPO), aligning with the objectives outlined in its Red Herring Prospectus.

Swapnil Shah, Managing Director of Senores Pharmaceuticals, expressed enthusiasm for this strategic expansion, highlighting the portfolio’s broad therapeutic coverage, including controlled substances and general category products. He emphasized that these drugs have high demand across multiple distribution channels, including government programs, retail pharmacies, and specialty clinics.

This acquisition not only enhances Senores Pharmaceuticals’ presence in the U.S. market but also strengthens its global reach in both regulated and semi-regulated markets, reinforcing its position as a key player in the pharmaceutical industry.